Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pulmonology

Standard of Care Treatment: Airway Clearance and Medications

At a Glance

The primary treatment for idiopathic bronchiectasis focuses on daily airway clearance therapy to remove mucus and prevent infections. Following a strict order—bronchodilator, hypertonic saline, clearance therapy, and then inhaled antibiotics—is essential for the medications to work effectively.

Managing idiopathic bronchiectasis is centered on one goal: breaking the “vicious cycle” of mucus buildup and infection. Because the condition is non-CF bronchiectasis, the treatment plan is specifically designed for unique airway needs, rather than being a “one-size-fits-all” approach borrowed from other diseases [1][2].

The Foundation: Airway Clearance

The most important part of a daily routine is Airway Clearance Therapy (ACT) [1]. Because the airways are widened and the natural cleaning mechanisms are damaged, patients must manually help move mucus out of their lungs [3].

  • Techniques: There is no single “best” technique. Options include Autogenic Drainage (a specialized way of breathing), the Active Cycle of Breathing Technique (ACBT), or using a PEP (Positive Expiratory Pressure) device like an Acapella or Aerobika [1][4].
  • Mucoactive Agents: To make clearing easier, doctors often prescribe hypertonic saline—a strong saltwater mist inhaled through a nebulizer. This pulls water into the mucus to thin it out, making it easier to cough up [5][6].

The “Order of Operations”

To maximize effectiveness, medications and clearance should follow a specific sequence. Doing these steps out of order can drastically reduce how well the inhaled medications work [1][2]:

  1. Bronchodilator: (If prescribed) Used first to open the airways.
  2. Hypertonic Saline: Used next to thin the mucus [5].
  3. Airway Clearance Therapy (ACT): Performed to physically clear the thinned mucus [3].
  4. Inhaled Antibiotics: (If prescribed) Used last so the medicine can coat the newly cleaned airway walls [7].

Safety Note: It is absolutely vital to rigorously clean and sterilize nebulizer cups and PEP devices daily. Using contaminated equipment can directly introduce dangerous bacteria back into the lungs [3].

Preventive Medications

For those who experience frequent flare-ups (usually three or more per year), long-term preventive medications may be considered [8][9].

  • Long-Term Macrolides: Low-dose antibiotics, most commonly azithromycin, are often used to reduce inflammation and prevent future flares [9][10]. Crucially, before starting this treatment, a doctor must screen the sputum for Nontuberculous Mycobacteria (NTM). Taking macrolides alone when an active NTM infection is present can cause the bacteria to become resistant, making it extremely difficult to treat [11]. Doctors will also monitor for side effects like gastrointestinal upset or tinnitus (ringing in the ears) [12][13].
  • Inhaled Antibiotics: For patients with chronic bacterial colonization (like Pseudomonas aeruginosa), inhaling antibiotics directly into the lungs can help keep the bacterial “load” low [14][15].

What to Avoid (and Why)

Treatments for other lung diseases cannot be blindly extrapolated to non-CF bronchiectasis. Some common treatments can be unhelpful or even harmful if used incorrectly:

  • Inhaled Corticosteroids (ICS): These are standard for asthma and COPD, but they are not recommended routinely for bronchiectasis [16][17]. Unless the patient has confirmed asthma or COPD alongside their bronchiectasis, these steroids may not help and could potentially increase the risk of lung infections [16].
  • Dornase Alfa (Pulmozyme): This is a highly effective drug for Cystic Fibrosis (CF), but clinical trials have shown it does not work well for non-CF bronchiectasis [18]. The mucus in non-CF bronchiectasis has a different chemical makeup, and using this drug can sometimes make symptoms worse in non-CF patients [19][20].

The Multidisciplinary Approach

Effective management requires a team. Working with a respiratory therapist to master clearance techniques and staying consistent with a preventive plan is the best way to maintain lung function and energy levels over the long term [21][2].

Common questions in this guide

What is the correct order of operations for my daily bronchiectasis treatments?
The recommended sequence is to first use a bronchodilator to open your airways, followed by hypertonic saline to thin the mucus. Next, perform airway clearance therapy to physically cough up the mucus, and finish with inhaled antibiotics so the medicine can coat the newly cleaned airway walls.
Why do I need to use hypertonic saline?
Hypertonic saline is a strong saltwater mist inhaled through a nebulizer. It works by pulling water into the airway mucus, which thins it out and makes it much easier to cough up during your clearance routine.
Can I use Pulmozyme (dornase alfa) for my non-CF bronchiectasis?
Dornase alfa is highly effective for cystic fibrosis, but clinical trials show it does not work well for non-CF bronchiectasis. Because the mucus has a different chemical makeup, using this drug can actually make symptoms worse in non-CF patients.
Should I use an inhaled corticosteroid for bronchiectasis?
Inhaled steroids are not routinely recommended for bronchiectasis unless you also have confirmed asthma or COPD. Using them without these other conditions may not help your symptoms and could potentially increase your risk of developing lung infections.
Why must I be tested for NTM before starting azithromycin?
Screening your sputum for Nontuberculous Mycobacteria (NTM) is crucial before starting long-term azithromycin. Taking this antibiotic while you have a hidden NTM infection can cause the bacteria to become resistant, making it extremely difficult to treat later.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you outline the exact 'Order of Operations' I should follow for my daily breathing treatments?
  2. 2.Given that I have non-CF bronchiectasis, why is it important that I avoid dornase alfa (Pulmozyme)?
  3. 3.If I don't have asthma or COPD, should we reconsider whether I need an inhaled corticosteroid?
  4. 4.Am I a candidate for long-term azithromycin, and have you screened my sputum for NTM before starting it?
  5. 5.What is the best daily method for cleaning and sterilizing my nebulizer cups and PEP devices?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Non-antimicrobial airway management of non-cystic fibrosis bronchiectasis.

    Egan AM, Clain JM, Escalante P

    Journal of clinical tuberculosis and other mycobacterial diseases 2018; (10()):24-28 doi:10.1016/j.jctube.2017.12.003.

    PMID: 31720381
  2. 2

    [Management of adult bronchiectasis - Consensus-based Guidelines for the German Respiratory Society (DGP) e. V. (AWMF registration number 020-030)].

    Ringshausen FC, Baumann I, de Roux A, et al.

    Pneumologie (Stuttgart, Germany) 2024; (78(11)):833-899 doi:10.1055/a-2311-9450.

    PMID: 39515342
  3. 3

    Pharmacotherapeutic strategies for treating bronchiectasis in pediatric patients.

    Lee E, Hong SJ

    Expert opinion on pharmacotherapy 2019; (20(8)):1025-1036 doi:10.1080/14656566.2019.1589453.

    PMID: 30897021
  4. 4

    Short-Term Effect of Autogenic Drainage on Ventilation Inhomogeneity in Adult Subjects With Stable Non-Cystic Fibrosis Bronchiectasis.

    Poncin W, Reychler G, Leeuwerck N, et al.

    Respiratory care 2017; (62(5)):524-531 doi:10.4187/respcare.05194.

    PMID: 28223466
  5. 5

    Re: Effectiveness of hypertonic saline nebulization in airway clearance in children with noncystic fibrosis bronchiectasis: A randomized control trial.

    Valji R, Mehta R, Hicks A

    Pediatric pulmonology 2021; (56(12)):4051-4052 doi:10.1002/ppul.25656.

    PMID: 34525261
  6. 6

    Inhaled Medications for Maintenance Therapy in Pediatric Noncystic Fibrosis Bronchiectasis.

    Harvath Gray EM, Pettit RS, Engdahl S

    The Annals of pharmacotherapy 2025; (59(5)):446-462 doi:10.1177/10600280241279602.

    PMID: 39297217
  7. 7

    Prescribing preferences and availability of nebulisers and inhalers for inhaled medications in bronchiectasis: results of a specialist survey.

    Shteinberg M, Spinou A, Goeminne P, et al.

    ERJ open research 2024; (10(1)) doi:10.1183/23120541.00724-2023.

    PMID: 38226061
  8. 8

    Prevention of exacerbations in patients with stable non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis of pharmacological and non-pharmacological therapies.

    Abu Dabrh AM, Hill AT, Dobler CC, et al.

    BMJ evidence-based medicine 2018; (23(3)):96-103 doi:10.1136/bmjebm-2018-110893.

    PMID: 29678900
  9. 9

    The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies.

    Li K, Liu L, Ou Y

    Journal of cardiothoracic surgery 2022; (17(1)):266 doi:10.1186/s13019-022-01882-y.

    PMID: 36221151
  10. 10

    Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis.

    Wang D, Fu W, Dai J

    Medicine 2019; (98(17)):e15285 doi:10.1097/MD.0000000000015285.

    PMID: 31027086
  11. 11

    Impacts of Nontuberculous Mycobacteria Isolates in Non-cystic Fibrosis Bronchiectasis: A 16-Year Cohort Study in Taiwan.

    Lin CY, Huang HY, Hsieh MH, et al.

    Frontiers in microbiology 2022; (13()):868435 doi:10.3389/fmicb.2022.868435.

    PMID: 35509319
  12. 12

    Efficacy and safety of long-term macrolide therapy for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis.

    Nakagawa N, Ito M, Asakura T, et al.

    Respiratory investigation 2024; (62(6)):1079-1087 doi:10.1016/j.resinv.2024.09.004.

    PMID: 39326270
  13. 13

    Dual antibiotics for bronchiectasis.

    Felix LM, Grundy S, Milan SJ, et al.

    The Cochrane database of systematic reviews 2018; (6()):CD012514 doi:10.1002/14651858.CD012514.pub2.

    PMID: 29889304
  14. 14

    Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis.

    Orriols R, Hernando R, Ferrer A, et al.

    Respiration; international review of thoracic diseases 2015; (90(4)):299-305 doi:10.1159/000438490.

    PMID: 26340658
  15. 15

    Inhaled antibiotics therapy for stable non-cystic fibrosis bronchiectasis: a meta-analysis.

    Xu MJ, Dai B

    Therapeutic advances in respiratory disease 2020; (14()):1753466620936866 doi:10.1177/1753466620936866.

    PMID: 32615859
  16. 16

    Inhaled corticosteroids for bronchiectasis.

    Kapur N, Petsky HL, Bell S, et al.

    The Cochrane database of systematic reviews 2018; (5()):CD000996 doi:10.1002/14651858.CD000996.pub3.

    PMID: 29766487
  17. 17

    British Thoracic Society guideline for bronchiectasis in adults.

    Hill AT, Sullivan AL, Chalmers JD, et al.

    BMJ open respiratory research 2018; (5(1)):e000348 doi:10.1136/bmjresp-2018-000348.

    PMID: 30687502
  18. 18

    The impact of dornase alfa on imaging features of bronchiectasis.

    Mingora CM, Mollica F, Caudri D, et al.

    Research square 2025; doi:10.21203/rs.3.rs-6991583/v1.

    PMID: 40951288
  19. 19

    Bronchoscopic instillation of DNase to manage refractory lobar atelectasis in a lung cancer patient.

    Assallum H, Song TY, DeLorenzo L, Harris K

    Annals of translational medicine 2019; (7(15)):363 doi:10.21037/atm.2019.05.15.

    PMID: 31516909
  20. 20

    Is there a place for dornase alfa therapy in lung transplantation?

    Harlander M, Vos R, Kneževič I

    Transplant international : official journal of the European Society for Organ Transplantation 2019; (32(6)):598-599 doi:10.1111/tri.13414.

    PMID: 30793383
  21. 21

    Medical management of bronchiectasis.

    O'Donnell AE

    Journal of thoracic disease 2018; (10(Suppl 28)):S3428-S3435 doi:10.21037/jtd.2018.09.39.

    PMID: 30505530

This page provides educational information about standard treatments for idiopathic bronchiectasis. Always consult your pulmonologist or respiratory therapist before changing your medication routine or airway clearance plan.

Get notified when new evidence is published on Idiopathic bronchiectasis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.